{"favorite_id": 10210, "calc_type": "", "dosing": false, "full_title_en": "PREVAIL Model for Prostate Cancer Survival", "short_title_en": "PREVAIL Model for Prostate Cancer", "medium_description_en": "Predicts overall survival in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.", "short_description_en": "Overall survival in metastatic prostate cancer.", "before_use": "<p>This calculator has not been externally validated.</p>", "instructions_en": "", "purpose_en": ["Prognosis"], "disease_en": ["Cancer", "Prostate Cancer"], "specialty_en": ["Hematology and Oncology", "Hospitalist Medicine", "Internal Medicine", "Urology"], "chief_complaint_en": ["Hematuria", "Weight Loss/Gain"], "system_en": ["Oncologic", "Urinary"], "search_abbreviation_en": ["PREVAIL model", "duke nomogram", "prostate cancer nomogram", "prostate cancer survival", "armstrong", "beer", "andrew armstrong", "tomasz beer"], "slug": "prevail-model-prostate-cancer-survival", "seo": {"meta_description_en": "The PREVAIL Model for Prostate Cancer Survival predicts overall survival in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.", "keywords_en": "PREVAIL model, duke nomogram, prostate cancer nomogram, prostate cancer survival"}, "content": {"how_to_use": {"use_case_en": "<p>Do you use the&nbsp;PREVAIL Model for Prostate Cancer and want to contribute your expertise?&nbsp;<a href=\"https://www.mdcalc.com/join-us\" target=\"_blank\">Join</a>&nbsp;our contributor team!</p>", "pearls_pitfalls_en": "", "why_use_en": ""}, "next_steps": {"advice_en": "<p>Do you use the&nbsp;PREVAIL Model for Prostate Cancer and want to contribute your expertise?&nbsp;<a href=\"https://www.mdcalc.com/join-us\" target=\"_blank\">Join</a>&nbsp;our contributor team!</p>", "management_en": "", "critical_actions_en": ""}, "about": {"formula_en": "<p dir=\"ltr\">Total score = (treatment x 18.1376) + [(ln(PSA) + 2.3026) x 9.52244917] + [(275.9 - time) x 0.1543483] + [(4.9 - albumin) x 16.0447656796] + [(16.8 - hemoglobin) x 7.7519235] + (neutrophil&nbsp;x 17.613) + (LDH x 19.00635) + (pain x 12.2248) + (bone x 17.7533) + (alkaline x 10.9685) + (spread x 32.991),</p>\n<p dir=\"ltr\">where variables are as follows (bolded):</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"*\" /><col width=\"*\" /><col width=\"*\" /></colgroup>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Variable</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Points</strong></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\"><b>Treatment</b> with enzalutamide planned</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\">Current<strong> PSA </strong>value, ng/mL</p>\n</td>\n<td>\n<p dir=\"ltr\">Continuous</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><b>Time</b> since diagnosis, months</p>\n</td>\n<td>\n<p dir=\"ltr\">Continuous</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Albumin</strong>, g/dL</p>\n</td>\n<td>\n<p dir=\"ltr\">Continuous</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Hemoglobin</strong>, g/dL</p>\n</td>\n<td>\n<p dir=\"ltr\">Continuous</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\"><b>Neutrophil</b> to lymphocyte ratio (neutrophil number divided by lymphocyte number) &lt;2.5</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\"><b>LDH </b>below upper limit of normal</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\"><strong>Pain</strong>&nbsp;0-1 (on a scale of 0-10, 10 being the worst pain imaginable, highest pain rating in last 24 hrs)</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\">&lt;10 <strong>bone</strong> metastases on bone scan</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\"><strong>Alkaline</strong> phosphatase&nbsp;less than upper limit of normal</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\">Pattern of <strong>spread</strong></p>\n</td>\n<td>\n<p dir=\"ltr\">No visceral liver metastases</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Any visceral liver metastases</p>\n</td>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p></p>", "more_info_en": "<p>Refer to Figure 1B in <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/30202945\" target=\"_blank\">Armstrong 2018</a> for nomogram for 1-year, 2-year, and 3-year survival.</p>\n<p>Refer to Figure 2 in <a href=\"https://pubmed.ncbi.nlm.nih.gov/32527692/\" target=\"_blank\">Armstrong 2020</a> for nomogram for 5-year survival.</p>", "evidence_based_medicine_en": "", "references_list": {"Original/Primary Reference": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/30202945", "text": "Armstrong AJ, Lin P, Higano CS, et al. Development and validation of a prognostic model for overall survival in chemotherapy-na\u00efve men with metastatic castration-resistant prostate cancer. Ann Oncol. 2018;29(11):2200-2207."}, {"href": "https://pubmed.ncbi.nlm.nih.gov/32527692/", "text": "Armstrong AJ, Lin P, Tombal B, et al. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-na\u00efve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. Eur Urol. 2020;9(6)."}], "Other References": [], "Validation": [], "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Outcomes": []}}, "contributor": {"expert_name": []}, "creator": [{"name": "Dr. Andrew J. Armstrong", "qa_en": "<p dir=\"ltr\"><strong>Why did you develop the PREVAIL Model for Prostate Cancer? Was there a particular clinical experience or patient encounter that inspired you to create this tool for clinicians?</strong></p>\n<p dir=\"ltr\">We desired a prognostic model for contemporary oncology practice, where men are commonly treated with a potent androgen receptor inhibitor such as enzalutamide prior to the use of docetaxel in the mCRPC treatment setting. This model was developed and validated using the phase 3 global PREVAIL study, and data can reasonably be extrapolated to any androgen receptor inhibitor in this setting, pending external validation.&nbsp;</p>\n<p dir=\"ltr\"><strong>What pearls, pitfalls and/or tips do you have for users of the PREVAIL Model for Prostate Cancer? Do you know of cases when it has been applied, interpreted, or used inappropriately?</strong></p>\n<p dir=\"ltr\">This model is only helpful if all of the variables are measured in the clinic, and we tried to include only those variables that are known to be valid predictors of overall survival in this setting and which are easy to collect in routine practice. External validation is planned as is an updated model with 5 year survival in the coming year. All results should be interpreted cautiously as results may be different based on prior therapies, differences in future therapies after enzalutamide, and the accuracy of this model is only about 70%, meaning that overestimates and underestimates of survival are possible.</p>\n<p dir=\"ltr\"><strong>What recommendations do you have for doctors once they have applied the PREVAIL Model for Prostate Cancer? Are there any adjustments or updates you would make to the score based on new data or practice changes?</strong></p>\n<p dir=\"ltr\">This model can provide a communication tool for patients and providers around prognosis and realistic expectations. This does NOT predict whether enzalutamide will work, and enzalutamide provided a survival benefit irrespective of these prognostic factors and is actually one of the variables used. Results can be updated based on PSA declines post-treatment (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/31274110\" target=\"_blank\">Armstrong 2019</a>) as well.</p>\n<p dir=\"ltr\"><strong>How do you use the PREVAIL Model for Prostate Cancer in your own clinical practice? Can you give an example of a scenario in which you use it?</strong></p>\n<p dir=\"ltr\">I use this to estimate survival and communicate this to patients, but I also update these prognostic estimates over time based on an individual patient's response to therapy, which can clearly improve prognosis. I give appropriate caveats given that the model is not perfect, individual outcomes do change and medical practice continues to improve with research advances. But this helps provide a communication framework to inform on treatment decisions and expectations.</p>\n<p dir=\"ltr\"><strong>Any other research in the pipeline that you&rsquo;re particularly excited about?</strong></p>\n<p><span id=\"docs-internal-guid-55309f8d-7fff-c6f3-8ada-adfaad09c2c4\"></p>\n<p dir=\"ltr\">Yes, we are working to update this model based on 5 year data and to externally validate this model in separate large datasets. We constantly strive to update these models as medical practice and treatments improve based on research.</p>", "approved": false, "creator_info": {"about_en": "<p>Andrew J. Armstrong, MD, is an oncologist at the Duke Cancer Institute (DCI) in Durham, NC. He is a professor of medicine and surgery, and an associate professor in pharmacology and cancer biology at the Duke University School of Medicine, as well as the director of research in the DCI's Center for Prostate and Urologic Cancer.  Dr. Armstrong\u2019s primary research is focused on drug development, biomarkers, and assessing the efficacy of new therapies, as well as improving survival prediction and prognostication in metastatic prostate cancer.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-andrew-j-armstrong.jpg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Armstrong+AJ%5BAuthor%5D"}}, {"name": "Dr. Tomasz M. Beer", "qa_en": "", "approved": false, "creator_info": {"about_en": "<p>Tomasz M. Beer, MD, FACP, is a medical oncologist and professor of medicine in the division of hematology/medical oncology at Oregon Health and Science University (OHSU). His primary research interests are clinical trials, preclinical investigation, and risk factors in prostate cancer. Dr. Beer is co-lead of the Beer and Qian Lab of the OHSU Knight Cancer Institute.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-tomasz-beer.jpg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Beer%20TM%5BAuthor%5D"}}], "reviewer": {"expert_name": []}, "related_resources": {"mdcalc_rating": [], "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "toggle", "label_en": "Treatment with enzalutamide planned", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "Yes", "value": 0}, {"label": "No", "value": 1}], "name": "treat"}, {"label_en": "Current <abbr title = \"Prostate-specific antigen\">PSA</abbr> value", "conditionality": "", "default": null, "tips_en": "", "optional": false, "name": "psa", "unit": "psa", "type": "textbox", "unit_info": {"name": "psa", "conversion": 1, "error_min": 0, "error_max": 10000, "warn_min": 0, "warn_max": 10000, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "ng/mL", "units_us": "ng/mL"}}, {"label_en": "Time since diagnosis", "conditionality": "", "default": null, "tips_en": "", "optional": false, "name": "time", "unit": "months", "type": "textbox", "unit_info": {"name": "months", "conversion": 1, "error_min": 0, "error_max": 1000, "warn_min": 0, "warn_max": 1000, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "months", "units_us": "months"}}, {"label_en": "Albumin", "conditionality": "", "default": null, "tips_en": "", "optional": false, "name": "alb", "unit": "alb", "type": "textbox", "unit_info": {"name": "Albumin", "conversion": 10, "error_min": 0, "error_max": 7, "warn_min": 1, "warn_max": 6, "normal_max_si": 55, "normal_min_si": 35, "normal_min_us": 3.5, "units_si": "g/L", "units_us": "g/dL", "normal_max_us": 5.5}}, {"label_en": "Hemoglobin", "conditionality": "", "default": null, "tips_en": "", "optional": false, "name": "hemo", "unit": "hgb", "type": "textbox", "unit_info": {"name": "Hemoglobin", "conversion": 10, "error_min": 0.5, "error_max": 25, "warn_min": 4, "warn_max": 20, "normal_max_si": 170, "normal_min_si": 120, "normal_min_us": 12, "units_si": "g/L", "units_us": "g/dL", "normal_max_us": 17}}, {"type": "radio", "label_en": "Neutrophil to lymphocyte ratio <2.5", "default": 0, "conditionality": "", "show_points": true, "tips_en": "Neutrophil number divided by lymphocyte number", "optional": false, "options": [{"label": "Yes", "value": 0}, {"label": "No", "value": 1}], "name": "nlr"}, {"type": "radio", "label_en": "<abbr title = \"Lactate dehydrogenase\">LDH</abbr> below upper limit of normal", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "Yes", "value": 0}, {"label": "No", "value": 1}], "name": "ldh"}, {"type": "radio", "label_en": "Pain 0-1", "default": 0, "conditionality": "", "show_points": true, "tips_en": "On a scale of 0-10, 10 being the worst pain imaginable, highest pain rating in last 24 hrs", "optional": false, "options": [{"label": "Yes", "value": 0}, {"label": "No", "value": 1}], "name": "pain"}, {"type": "radio", "label_en": "<10 bone metastases on bone scan", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "Yes", "value": 0}, {"label": "No", "value": 1}], "name": "bone"}, {"type": "radio", "label_en": "Alkaline phosphatase less than upper limit of normal", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "Yes", "value": 0}, {"label": "No", "value": 1}], "name": "alp"}, {"type": "radio", "label_en": "Pattern of spread", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No visceral liver metastases", "value": 0}, {"label": "Any visceral liver metastases", "value": 1}], "name": "spread"}], "md5": "", "cmeReleaseDate": null, "cmeEndDate": null, "cmeLastReviewed": null, "related_calcs": [{"calcId": 2049, "short_title_en": "D'Amico Classification", "slug": "damico-risk-classification-prostate-cancer"}, {"calcId": 2153, "short_title_en": "MSKCC/Motzer Criteria for RCC", "slug": "memorial-sloan-kettering-cancer-center-mskcc-motzer-score-metastatic-renal-cell-carcinoma-rcc"}, {"calcId": 3925, "short_title_en": "Fong Score", "slug": "fong-clinical-risk-score-colorectal-cancer-recurrence"}]}